The U.S. stock market breathed a collective sigh of relief as lawmakers neared a deal to end the government shutdown, sending stock futures soaring. This news comes after a period of uncertainty, with the shutdown dragging on for a historic 39 days, impacting both the economy and investor sentiment.
S&P 500 futures saw a 0.4% increase, while Nasdaq-100 futures climbed 0.6%. Futures tied to the Dow Jones Industrial Average also rose, gaining 123 points, or 0.3%.
The potential deal, being discussed on a Sunday, aims to reopen the government into January and reverse some of the recent federal layoffs. Sources suggest that enough Democratic senators were on board to reach the required 60-vote minimum for approval. If the Senate passes the deal, it would then need approval from the House of Representatives and the President before the shutdown officially ends.
But here's where it gets controversial... The proposed agreement includes future protections for government workers, but notably doesn't extend ACA credits, a key point of contention for many Democrats. Instead, it calls for a vote on these subsidies in December.
The ongoing shutdown has significantly impacted consumer sentiment, driving it to its lowest level in over three years, according to a University of Michigan survey. Furthermore, the closure has caused delays in the release of crucial economic reports, such as the Consumer Price Index and Producer Price Index, adding to the market's anxieties.
And this is the part most people miss... The stock market was already reeling from a tough week due to concerns about high valuations in artificial intelligence-related stocks. The Nasdaq Composite experienced its worst week since the tariff-driven selloff in April, losing 3%. The S&P 500 fell 1.6%, and the Dow Jones Industrial Average dropped 1.2%.
Investors are also keeping an eye on upcoming earnings reports, including Walt Disney's quarterly results.
"A risk-off rally on tech AI stalwart names such as Microsoft, Palantir, Nvidia among others has put some near-term concern in this tech bull market," stated Wedbush analyst Dan Ives in a note to clients on Sunday.
In other news, pharmaceutical giant Pfizer has clinched a $10 billion deal to acquire obesity drug developer Metsera. This deal comes after a bidding war with Danish competitor Novo Nordisk. Pfizer will pay $86.25 per share in cash, including a contingent value right for additional payments.
Senate Democrats are reportedly signaling openness to a deal to reopen the government, according to Bloomberg News. The lawmakers are said to be more open to voting on a spending package, provided a few budget details are finalized, including a provision to protect federal workers from job cuts.
What do you think? Does this potential deal adequately address the issues, or are there still significant concerns? Share your thoughts in the comments below!
